ClinicalTrials.gg
CompletedNCT01381874Updated Apr 11, 2019Results posted

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

A Phase 2 interventional study of Exemestane and Abiraterone acetate + Prednisone/ Prednisolone + Exemestane in Metastatic ER+ Her2- Breast Cancer and Postmenopausal, sponsored by Janssen Research & Development, LLC. Completed at 85 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-11.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Breast Neoplasms by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Johnson & Johnson.

Enrollment
5th of 18
297 · median 114
Started
2011
the only one that year
Phase 2
7 of 19
none open now
Registered
13th of 19
by date

Among the 19 studies in Breast Neoplasms by Johnson & Johnson, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 2, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 19 studies in Breast Neoplasms by Johnson & Johnson is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Breast Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.

Read the detailed description

This is a randomized (study drug assigned by chance), open-label (all participants will know the identity of the assigned study drug) study divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. The treatment phase will comprise a series of 28-day cycles with continuous study treatment until breast cancer progression, when an end-of-treatment visit will be completed before the follow-up phase begins. The duration of participation in the study for an individual patient may be up to approximately 7 years, including follow-up evaluations. Patients will be evaluated for the safety and effectiveness of study treatments. During the treatment phase, patients will take the following study drugs by mouth once daily: abiraterone acetate, 1 g/day, as four 250-mg tablets, on an empty stomach, and patients must not eat for at least 1 hour after abiraterone acetate; prednisone (prednisolone when prednisone is not available), 5 mg/day; and exemestane, 25 mg/day, as a single tablet. The treatment phase will consist of a series of 28-day cycles with continuous study treatment until breast cancer progression. At the planned interim analysis, the Data Review Committee has recommended that further randomization to the abiraterone acetate alone group be stopped and that the study is to be continued otherwise.

03

Conditions studied

  • Metastatic ER+ Her2- Breast Cancer
  • Postmenopausal

Keywords

  • Breast cancer
  • Abiraterone
  • Postmenopausal
  • Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients must be
  • ER+, Human epidermal growth factor receptor 2 (Her2) negative breast cancer
  • Disease must have been sensitive to anastrozole or letrozole therapy prior to disease progression
  • No more than two in the metastatic setting, of which no more than one was chemotherapy
  • (ECOG) performance status score of \<=1
  • Patients with disease confined only to bone may be included, but patients with purely sclerotic lesions may not participate in the study

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with exemestane, ketoconazole, aminoglutethimide, or a CYP17 inhibitor. Prior treatment with ketoconazole for \<= 7 days is permitted and topical formulations of ketoconazole are permitted
  • Potential patients must not have taken anastrozole, letrozole, fulvestrant, or any chemotherapy for at least 2 weeks (bevacizumab for at least 3 weeks) before randomization
  • Anticancer immunotherapy or agent within 4 weeks before randomization, or anticancer radiotherapy (except palliative) or anticancer endocrine therapy within 2 weeks before randomization
  • Serious or uncontrolled nonmalignant disease, including active or uncontrolled infection
  • Clinical or biochemical evidence of hyperaldosteronism or hypopituitarism
  • Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
297 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate + Prednisone or Prednisolone

    Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.

    Drug: Abiraterone acetate + Prednisone or Prednisolone

  • Experimental
    Abiraterone acetate + Prednisone/Prednisolone + Exemestane

    Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.

    Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane

  • Experimental
    Exemestane

    Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.

    Drug: Exemestane

Interventions

  • Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets

  • DrugAbiraterone acetate + Prednisone/ Prednisolone + Exemestane

    Drug pages: Abiraterone Acetate · Prednisone · Prednisolone · Exemestane

    Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.

  • DrugAbiraterone acetate + Prednisone or Prednisolone

    Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.

    Time frame: Approximately 2 years

  2. Overall Survival (OS)

    OS was calculated as the time from randomization to death from any cause.

    Time frame: Approximately 3 years

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall response rate was defined as the percentage of participants with measurable disease achieving a best overall response of either complete response (CR) or partial response (PR) based on RECIST. CR: disappearance of all target lesions and non-target lesions. PR: at least a 30 percent (%) decrease in the sum of longest diameter (LD) of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: Approximately 2 years

  2. Clinical Benefit Rate

    Clinical benefit rate was defined as the percentage of participants with measurable disease achieving a best overall response of a CR, PR, or stable disease (SD) for at least 6 months based on RECIST. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.

    Time frame: Approximately 2 years

  3. Duration of Response

    Duration of objective response was measured from the first time that the CR or PR was achieved to the first observation of disease progression (either radiographic or clinical) based on the RECIST criteria.

    Time frame: Approximately 2 years

  4. Change From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment

    Change from baseline in serum endocrine biomarkers (estradiol and estrone) was summarized by treatment at end of treatment.

    Time frame: Baseline and End of treatment (approximately 2 years)

  5. Change From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment

    Change from baseline in serum endocrine biomarkers (Progesterone and Testosterone) was summarized by treatment at end of treatment.

    Time frame: Baseline and End of treatment (approximately 2 years)

07

Results

Posted Jul 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Started10289106
Treated10287104
Completed252630
Not completed776376
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject9109
Withdrew: Other675267

Outcome measures

PrimaryProgression-Free Survival (PFS)

Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.

Time frame:
Approximately 2 years
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Progression-Free Survival (PFS)3.68 (1.94 to 5.26)3.65 (2.73 to 5.59)4.47 (3.68 to 5.59)
Statistical analysis
  • Exemestane vs Abiraterone Acetate + Prednisone · stratified log-rank test · p = 0.437 · Hazard ratio (hr): 1.143 · 95% CI 0.816 to 1.603
  • Exemestane vs Abiraterone Acetate + Exemestane + Prednisone · stratified log-rank test · p = 0.794 · Hazard ratio (hr): 0.958 · 95% CI 0.695 to 1.320
PrimaryOverall Survival (OS)

OS was calculated as the time from randomization to death from any cause.

Time frame:
Approximately 3 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Overall Survival (OS)NA (NA to NA)26.41 (23.49 to NA)NA (23.79 to NA)
Statistical analysis
  • Exemestane vs Abiraterone Acetate + Prednisone · stratified log-rank test · p = 0.807 · Hazard ratio (hr): 1.074 · 95% CI 0.608 to 1.896
  • Exemestane vs Abiraterone Acetate + Exemestane + Prednisone · stratified log-rank test · p = 0.542 · Hazard ratio (hr): 1.183 · 95% CI 0.688 to 2.036
SecondaryOverall Response Rate (ORR)

Overall response rate was defined as the percentage of participants with measurable disease achieving a best overall response of either complete response (CR) or partial response (PR) based on RECIST. CR: disappearance of all target lesions and non-target lesions. PR: at least a 30 percent (%) decrease in the sum of longest diameter (LD) of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
Approximately 2 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Overall Response Rate (ORR)6.35.812.1
Statistical analysis
  • Exemestane vs Abiraterone Acetate + Prednisone · Fisher Exact · p = 1.000 · Risk ratio (rr): 0.909 · 95% CI 0.213 to 3.878
  • Exemestane vs Abiraterone Acetate + Exemestane + Prednisone · Fisher Exact · p = 0.366 · Risk ratio (rr): 1.909 · 95% CI 0.605 to 6.026
SecondaryClinical Benefit Rate

Clinical benefit rate was defined as the percentage of participants with measurable disease achieving a best overall response of a CR, PR, or stable disease (SD) for at least 6 months based on RECIST. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.

Time frame:
Approximately 2 years
Reported as:
Number · Percentage of participants
Clinical Benefit Rate
Percentage of participantsExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Clinical Benefit Rate12.79.622.7
Statistical analysis
  • Exemestane vs Abiraterone Acetate + Prednisone · Chi-squared · p = 0.603 · Risk ratio (rr): 0.757 · 95% CI 0.264 to 2.175
  • Exemestane vs Abiraterone Acetate + Exemestane + Prednisone · Chi-squared · p = 0.137 · Risk ratio (rr): 1.790 · 95% CI 0.816 to 3.926
SecondaryDuration of Response

Duration of objective response was measured from the first time that the CR or PR was achieved to the first observation of disease progression (either radiographic or clinical) based on the RECIST criteria.

Time frame:
Approximately 2 years
Reported as:
Median · months
Duration of Response
monthsExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Duration of Response6.47 (NA to NA)4.86 (4.63 to NA)6.93 (4.57 to NA)
SecondaryChange From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment

Change from baseline in serum endocrine biomarkers (estradiol and estrone) was summarized by treatment at end of treatment.

Time frame:
Baseline and End of treatment (approximately 2 years)
Reported as:
Mean · Picomoles Per Liter (Pmol/L)
Change From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment
Picomoles Per Liter (Pmol/L)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Estradiol1.53 ± 27.643-3.35 ± 13.634-1.04 ± 20.146
Estrone-34.20 ± 83.770-28.09 ± 47.779-30.60 ± 42.385
SecondaryChange From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment

Change from baseline in serum endocrine biomarkers (Progesterone and Testosterone) was summarized by treatment at end of treatment.

Time frame:
Baseline and End of treatment (approximately 2 years)
Reported as:
Mean · Nanomoles Per Liter (nmol/L)
Change From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment
Nanomoles Per Liter (nmol/L)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
Progesterone-4.80 ± 18.2688.98 ± 15.11312.34 ± 16.967
Testosterone-0.09 ± 0.416-0.51 ± 0.459-0.48 ± 0.323

Adverse events

Collected over Approximately 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exemestane1/102 (1%)12/102 (11.8%)79/102 (77.5%)
Abiraterone Acetate + Prednisone0/87 (0%)18/87 (20.7%)76/87 (87.4%)
Abiraterone Acetate + Exemestane + Prednisone2/104 (1.9%)28/104 (26.9%)84/104 (80.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
HypokalaemiaMetabolism and nutrition disorders1/1023/870/104
Abdominal PainGastrointestinal disorders0/1020/873/104
VomitingGastrointestinal disorders0/1020/873/104
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1020/873/104
Back PainMusculoskeletal and connective tissue disorders0/1022/870/104
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders0/1022/870/104
Pathological FractureMusculoskeletal and connective tissue disorders0/1022/870/104
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/1021/872/104
Atrial FibrillationCardiac disorders0/1021/871/104
Crohn's DiseaseGastrointestinal disorders0/1021/870/104
Most frequent other events
Showing 10 of 38
Most frequent other events
EventExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + Prednisone
FatigueGeneral disorders27/10224/8721/104
NauseaGastrointestinal disorders18/10221/8722/104
HypokalaemiaMetabolism and nutrition disorders4/10219/8714/104
VomitingGastrointestinal disorders7/10212/8719/104
Bone PainMusculoskeletal and connective tissue disorders18/10213/8713/104
Back PainMusculoskeletal and connective tissue disorders12/10215/8717/104
ArthralgiaMusculoskeletal and connective tissue disorders17/1028/8711/104
Decreased AppetiteMetabolism and nutrition disorders11/10213/8717/104
ConstipationGastrointestinal disorders9/10214/8715/104
Hot FlushVascular disorders14/10214/879/104

Baseline characteristics

Age, Continuous
Age, Continuous(years)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + PrednisoneTotal
Mean61.9 ± 8.5563.1 ± 9.1763.8 ± 10.9162.9 ± 9.63
Sex: Female, Male
Sex: Female, Male(Participants)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + PrednisoneTotal
Female10289106297
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + PrednisoneTotal
Hispanic or Latino0213
Not Hispanic or Latino847295251
Unknown or Not Reported18151043
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + PrednisoneTotal
American Indian or Alaska Native0000
Asian1157
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White927696264
More than one race0112
Unknown or Not Reported911424
Region of Enrollment
Region of Enrollment(Participants)ExemestaneAbiraterone Acetate + PrednisoneAbiraterone Acetate + Exemestane + PrednisoneTotal
USA911828
Belgium18212160
France17131141
Spain1171230
United Kingdom7121130
Italy0145
Korea, Republic Of1056
Netherlands85821
Russia20121951
Ukraine117725
08

Study locations

85 sites
  • Muscle Shoals, Alabama, United States
  • Fresno, California, United States
  • Los Angeles, California, United States
  • Monterey, California, United States
  • Chicago, Illinois, United States
  • Waterville, Maine, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Henderson, Nevada, United States
  • East Syracuse, New York, United States
  • Johnson City, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Fargo, North Dakota, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Kettering, Ohio, United States
  • Portland, Oregon, United States
  • Sioux Falls, South Dakota, United States
  • Dallas, Texas, United States
  • El Paso, Texas, United States
  • Houston, Texas, United States
  • Tyler, Texas, United States
  • Seattle, Washington, United States
  • Antwerpen, Belgium
  • Brussels, Belgium
  • Brussel, Belgium
  • Bruxelles, Belgium
  • Duffel, Belgium
  • Edegem, Belgium
  • Gent, Belgium
  • Hasselt, Belgium
  • Leuven, Belgium
  • Liège, Belgium
  • Wilrijk, Belgium
  • Bordeaux, France
  • Caen Cedex 05, France
  • Pierre Benite, France
  • Saint Herblain, France
  • Saint-cloud, France
  • Galway, Ireland
  • Limerick, Ireland
  • Busan, Korea, Republic of
  • Seoul, Korea, Republic of
  • Suwon, Korea, Republic of
  • Luxembourg, Luxembourg
  • Niederkorn, Luxembourg
  • Alkmaar, Netherlands
  • Amsterdam, Netherlands
  • Heerlen, Netherlands
  • Leeuwarden, Netherlands
  • Leiden, Netherlands
  • Rotterdam, Netherlands
  • Sittard, Netherlands
  • Bialystok, Poland
  • Warszawa, Poland
  • Chelyabinsk, Russian Federation
  • Kazan, Russian Federation
  • Leningrad Region, Russian Federation
  • Moscow, Russian Federation
  • Saint-Petersburg,, Russian Federation
  • Sochi, Russian Federation
  • St Petersburg, Russian Federation
  • Stavropol, Russian Federation
  • Vladimir, Russian Federation
  • Barcelona, Spain
  • Madrid N/a, Spain
  • Madrid, Spain
  • Sevilla, Spain
  • Valencia, Spain
  • Chernivtsi, Ukraine
  • Dnepropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Kharkov, Ukraine
  • Odessa, Ukraine
  • Tcherkassy, Ukraine
  • Uzhgorod, Ukraine
  • Bath, United Kingdom
  • Birmingham, United Kingdom
  • Exeter, United Kingdom
  • London, United Kingdom
  • Nottingham, United Kingdom
  • Plymouth, United Kingdom
  • Sheffield, United Kingdom
  • Sutton, United Kingdom
09

References and documents

Publications

  • O'Shaughnessy J, Campone M, Brain E, Neven P, Hayes D, Bondarenko I, Griffin TW, Martin J, De Porre P, Kheoh T, Yu MK, Peng W, Johnston S. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol. 2016 Jan;27(1):106-13. doi: 10.1093/annonc/mdv487. Epub 2015 Oct 26. PubMed 26504153 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Jul 2014, 35 months.

Results were first posted in Jul 2018, 3 years 11 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 35 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Jun 27, 2011
StartActual
Aug 24, 2011
Primary completionActual
Jul 28, 2014
CompletionActual
Aug 8, 2018
Results first posted
Jul 27, 2018
Last update
Apr 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01381874
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Aug 24, 2011
Primary completion
Jul 28, 2014
Completion
Aug 8, 2018
Results posted
Jul 27, 2018
Last update
Apr 11, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Prednisone · Prednisolone · Exemestane

Start the discussion